Division of Vascular Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.
Division of Vascular Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.
J Vasc Surg Venous Lymphat Disord. 2017 Mar;5(2):171-176.e1. doi: 10.1016/j.jvsv.2016.11.005. Epub 2017 Jan 16.
Systemic thrombolysis (ST) and catheter-directed intervention (CDI) are both used in the treatment of acute pulmonary embolism (PE), but the comparative outcomes of these two therapies remain unclear. The objective of this study was to compare short-term mortality and safety outcomes between the two treatments using a large national database.
Patients presenting with acute PE were identified in the National Inpatient Sample (NIS) from 2009 to 2012. Comorbidities, clinical characteristics, and invasive procedures were identified using International Classification of Diseases, Ninth Revision (ICD) codes and the Elixhauser comorbidity index. To adjust for anticipated baseline differences between the two treatment groups, propensity score matching was used to create a matched ST cohort with clinical and comorbid characteristics similar to those of the CDI cohort. Subgroups of patients with and without hemodynamic shock were analyzed separately. Primary outcomes were in-hospital mortality, overall bleeding risk, and hemorrhagic stroke risk.
Of 263,955 subjects with acute PE, 1.63% (n = 4272) received ST and 0.55% (n = 1455) received CDI. ST subjects were older, had more chronic comorbidities, and had higher rates of respiratory failure (ST, 27.9% [n = 1192]; CDI, 21.2% [n = 308]; P < .001) and shock (ST, 18.2% [n = 779]; CDI, 12% [n = 174]; P < .001). CDI subjects had higher rates of concurrent deep venous thrombosis (ST, 35.8% [n = 1530]; CDI, 45.9% [n = 668]; P < .001) and vena cava filter placement (ST, 31.1% [n = 1328]; CDI, 57% [n = 830]; P < .001). In the unmatched cohort, ST subjects had higher in-hospital mortality (ST, 16.7% [n = 714]; CDI, 9.4% [n = 136]; P < .001) and hemorrhagic stroke rates (ST, 2.2% [n = 96]; CDI, 1.4% [n = 20]; P = .041). After propensity matching, 1430 patients remained in each cohort; baseline characteristics of the matched cohorts did not differ significantly using standardized difference comparisons. Analysis of the matched cohorts did not demonstrate a significant effect of CDI on in-hospital mortality or overall bleeding risk but did show a significant protective effect against hemorrhagic stroke compared with ST (odds ratio, 0.47; 95% confidence interval, 0.27-0.82; P = .01). Subgroup analysis showed decreased odds of hemorrhagic stroke for CDI in the nonshock subgroup and increased procedural bleeding for CDI but no difference in hemorrhagic stroke risk in the shock subgroup.
ST for acute PE may not improve in-hospital mortality compared with CDI but increases the overall risk of hemorrhagic stroke compared with CDI. Further prospective studies should examine the comparative effectiveness and safety of these two treatments.
全身溶栓(ST)和导管定向干预(CDI)均用于治疗急性肺栓塞(PE),但这两种治疗方法的短期疗效尚不清楚。本研究的目的是使用大型国家数据库比较这两种治疗方法的短期死亡率和安全性结果。
2009 年至 2012 年,从国家住院患者样本(NIS)中确定急性 PE 患者。使用国际疾病分类,第 9 版(ICD)代码和 Elixhauser 合并症指数识别合并症、临床特征和侵入性程序。为了调整两组治疗预期的基线差异,使用倾向评分匹配创建具有与 CDI 队列相似的临床和合并症特征的匹配 ST 队列。分析了有和没有血流动力学休克的亚组患者。主要结局是住院死亡率、总出血风险和出血性卒中风险。
在 263955 名急性 PE 患者中,1.63%(n=4272)接受 ST,0.55%(n=1455)接受 CDI。ST 组患者年龄较大,合并慢性疾病更多,呼吸衰竭发生率更高(ST,27.9%[n=1192];CDI,21.2%[n=308];P<0.001)和休克(ST,18.2%[n=779];CDI,12%[n=174];P<0.001)。CDI 组患者同时发生深静脉血栓形成的比例更高(ST,35.8%[n=1530];CDI,45.9%[n=668];P<0.001)和腔静脉滤器放置比例更高(ST,31.1%[n=1328];CDI,57%[n=830];P<0.001)。在未匹配的队列中,ST 组患者的住院死亡率更高(ST,16.7%[n=714];CDI,9.4%[n=136];P<0.001)和出血性卒中发生率更高(ST,2.2%[n=96];CDI,1.4%[n=20];P=0.041)。在进行倾向评分匹配后,每个队列中仍有 1430 名患者;使用标准化差异比较,匹配队列的基线特征没有显著差异。对匹配队列的分析表明,与 ST 相比,CDI 对住院死亡率或总出血风险没有显著影响,但对出血性卒中有显著的保护作用(比值比,0.47;95%置信区间,0.27-0.82;P=0.01)。亚组分析表明,CDI 可降低非休克亚组出血性卒中的几率,并增加 CDI 的手术出血,但在休克亚组中出血性卒中风险无差异。
与 CDI 相比,ST 治疗急性 PE 可能不会提高住院死亡率,但与 CDI 相比,ST 会增加出血性卒中的总体风险。需要进一步的前瞻性研究来检查这两种治疗方法的比较效果和安全性。